Luis Ricardo Balleza Alejandri, Fernando Grover Páez, Erick González Campos, Carlos G Ramos Becerra, Ernesto Germán Cardona Muñóz, Sara Pascoe González, María Guadalupe Ramos Zavala, Africa Samantha Reynoso Roa, Daniel Osmar Suárez Rico, Alberto Beltrán Ramírez, Jesús Jonathan García Galindo, David Cardona Müller, Claudia Yanette Galán Ruíz
{"title":"Empagliflozin 和 Dapagliflozin 可改善墨西哥 2 型糖尿病患者的内皮功能：双盲临床试验。","authors":"Luis Ricardo Balleza Alejandri, Fernando Grover Páez, Erick González Campos, Carlos G Ramos Becerra, Ernesto Germán Cardona Muñóz, Sara Pascoe González, María Guadalupe Ramos Zavala, Africa Samantha Reynoso Roa, Daniel Osmar Suárez Rico, Alberto Beltrán Ramírez, Jesús Jonathan García Galindo, David Cardona Müller, Claudia Yanette Galán Ruíz","doi":"10.3390/jcdd11060182","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>To assess the acute effect of empagliflozin versus dapagliflozin administration on flow-mediated vasodilation in patients with type 2 diabetes mellitus.</p><p><strong>Design: </strong>A double-blind clinical trial, at the Experimental and Clinical Therapeutics Institute, University Health Sciences Center, at the Universidad de Guadalajara, in inpatients with T2D according to the 2023 ADA criteria.</p><p><strong>Methods: </strong>Thirty patients (15 males and 15 females), aged between 35 and 65 years, were included in this study, according to the 2023 ADA criteria. The eligible patients were randomly assigned to three groups: empagliflozin 25 mg once daily, dapagliflozin 10 mg once daily, or placebo once daily. Anthropometric parameters were taken using validated techniques. FMD was measured using a high-resolution semiautomatic ultrasound UNEX-EF 38G (UNEX Co., Ltd., Nagoya, Japan). Arterial tension was determined with the OMRON electronic digital sphygmomanometer (HEM 907 XL, Kyoto, Japan).</p><p><strong>Results: </strong>The group of patients who received empagliflozin had a significantly lower baseline flow-mediated dilation (FMD) compared to the group receiving dapagliflozin (<i>p</i> = 0.017); at the end of this study, the empagliflozin group achieved a comparable FMD to the dapagliflozin group (<i>p</i> = 0.88).</p><p><strong>Conclusion: </strong>After the treatment period, the empagliflozin and dapagliflozin groups achieved similar FMD, suggesting a class effect.</p>","PeriodicalId":15197,"journal":{"name":"Journal of Cardiovascular Development and Disease","volume":null,"pages":null},"PeriodicalIF":2.4000,"publicationDate":"2024-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11204032/pdf/","citationCount":"0","resultStr":"{\"title\":\"Empagliflozin and Dapagliflozin Improve Endothelial Function in Mexican Patients with Type 2 Diabetes Mellitus: A Double-Blind Clinical Trial.\",\"authors\":\"Luis Ricardo Balleza Alejandri, Fernando Grover Páez, Erick González Campos, Carlos G Ramos Becerra, Ernesto Germán Cardona Muñóz, Sara Pascoe González, María Guadalupe Ramos Zavala, Africa Samantha Reynoso Roa, Daniel Osmar Suárez Rico, Alberto Beltrán Ramírez, Jesús Jonathan García Galindo, David Cardona Müller, Claudia Yanette Galán Ruíz\",\"doi\":\"10.3390/jcdd11060182\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aim: </strong>To assess the acute effect of empagliflozin versus dapagliflozin administration on flow-mediated vasodilation in patients with type 2 diabetes mellitus.</p><p><strong>Design: </strong>A double-blind clinical trial, at the Experimental and Clinical Therapeutics Institute, University Health Sciences Center, at the Universidad de Guadalajara, in inpatients with T2D according to the 2023 ADA criteria.</p><p><strong>Methods: </strong>Thirty patients (15 males and 15 females), aged between 35 and 65 years, were included in this study, according to the 2023 ADA criteria. The eligible patients were randomly assigned to three groups: empagliflozin 25 mg once daily, dapagliflozin 10 mg once daily, or placebo once daily. Anthropometric parameters were taken using validated techniques. FMD was measured using a high-resolution semiautomatic ultrasound UNEX-EF 38G (UNEX Co., Ltd., Nagoya, Japan). Arterial tension was determined with the OMRON electronic digital sphygmomanometer (HEM 907 XL, Kyoto, Japan).</p><p><strong>Results: </strong>The group of patients who received empagliflozin had a significantly lower baseline flow-mediated dilation (FMD) compared to the group receiving dapagliflozin (<i>p</i> = 0.017); at the end of this study, the empagliflozin group achieved a comparable FMD to the dapagliflozin group (<i>p</i> = 0.88).</p><p><strong>Conclusion: </strong>After the treatment period, the empagliflozin and dapagliflozin groups achieved similar FMD, suggesting a class effect.</p>\",\"PeriodicalId\":15197,\"journal\":{\"name\":\"Journal of Cardiovascular Development and Disease\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2024-06-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11204032/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Cardiovascular Development and Disease\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3390/jcdd11060182\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cardiovascular Development and Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/jcdd11060182","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
Empagliflozin and Dapagliflozin Improve Endothelial Function in Mexican Patients with Type 2 Diabetes Mellitus: A Double-Blind Clinical Trial.
Aim: To assess the acute effect of empagliflozin versus dapagliflozin administration on flow-mediated vasodilation in patients with type 2 diabetes mellitus.
Design: A double-blind clinical trial, at the Experimental and Clinical Therapeutics Institute, University Health Sciences Center, at the Universidad de Guadalajara, in inpatients with T2D according to the 2023 ADA criteria.
Methods: Thirty patients (15 males and 15 females), aged between 35 and 65 years, were included in this study, according to the 2023 ADA criteria. The eligible patients were randomly assigned to three groups: empagliflozin 25 mg once daily, dapagliflozin 10 mg once daily, or placebo once daily. Anthropometric parameters were taken using validated techniques. FMD was measured using a high-resolution semiautomatic ultrasound UNEX-EF 38G (UNEX Co., Ltd., Nagoya, Japan). Arterial tension was determined with the OMRON electronic digital sphygmomanometer (HEM 907 XL, Kyoto, Japan).
Results: The group of patients who received empagliflozin had a significantly lower baseline flow-mediated dilation (FMD) compared to the group receiving dapagliflozin (p = 0.017); at the end of this study, the empagliflozin group achieved a comparable FMD to the dapagliflozin group (p = 0.88).
Conclusion: After the treatment period, the empagliflozin and dapagliflozin groups achieved similar FMD, suggesting a class effect.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
